Research programme: metabotropic glutamate receptor positive allosteric modulators - Domain Therapeutics

Drug Profile

Research programme: metabotropic glutamate receptor positive allosteric modulators - Domain Therapeutics

Alternative Names: DT 1687; DT 2208; DT2228; mGluR PAM - Domain Therapeutics; mGluR2 PAM; mGluR3 PAM; mGluR4 PAMs

Latest Information Update: 24 Oct 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Faust Pharmaceuticals
  • Developer Domain Therapeutics; Prexton Therapeutics
  • Class Small molecules
  • Mechanism of Action Metabotropic glutamate receptor 2 modulators; Metabotropic glutamate receptor 3 modulators; Metabotropic glutamate receptor 4 modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Parkinson's disease
  • No development reported Anxiety disorders
  • Discontinued Pain; Schizophrenia

Most Recent Events

  • 22 Oct 2016 Research development is ongoing in Parkinson's disease in France (PO)
  • 16 Jul 2016 No recent reports of development identified for research development in Anxiety-disorders in France (PO)
  • 16 Jul 2016 No recent reports of development identified for research development in Parkinson's-disease in France (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top